This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1911303 (2019)
Related article
Nassif, M. & Kosiborod, M. Effect of glucose-lowering therapies on heart failure. Nat. Rev. Cardiol. 15, 282–291 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huynh, K. Dapagliflozin — a breakthrough in the search for drugs to treat HFrEF. Nat Rev Cardiol 16, 700 (2019). https://doi.org/10.1038/s41569-019-0291-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-019-0291-1